Abstract: Applicant discloses methods for treating a glucocorticoid receptor positive (GR+) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in subject. The GR+ neuroepithelial tumor may be a neurofibromatosis type 2 (NF 2) tumor; the GR+ neuroepithelial tumor may be a schwannoma, meningioma, or ependymoma. In embodiments, the GR+ neuroepithelial tumor is not an adrenocorticotropic hormone (ACTH)-secreting tumor. In embodiments, the SGRM comprises a steroidal backbone. In embodiments, the SGRM is mifepristone. In embodiments, the SGRM comprises a non-steroidal backbone, such as, e.g., a cyclohexyl pyrimidine, a fused azadecalin, a heteroaryl ketone fused azadecalin, or an octahydro fused azadecalin backbone. The SGRM may be administered orally. The SGRM may be administered alone. In embodiments, the SGRM is administered with at least one non-SGRM therapy, e.g.

Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of specific diseases or conditions.

Abstract: The present disclosure provides four monocarborane cluster-containing platinum complexes and a preparation method and an OLED application.

Abstract: An organic light-emitting device includes: a first electrode; a second electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1.

Abstract: The present invention relates to a pyridine derivative of formula (1) wherein R1 is optionally-substituted C1-6 alkyl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered saturated or partially-unsaturated heterocyclyl; R2 is halogen atom, cyano, C1-6 alkyl which may be optionally substituted with 1 to 3 the same or different halogen atoms, C1-6 alkoxy which may be optionally substituted with 1 to 3 the same or different halogen atoms, or amino which may be optionally substituted with 1 to 2 the same or different C1-6 alkyl; and the bind with broken line is single or double bond, or a pharmaceutically acceptable salt thereof, which is useful as a medicament for treating symptoms in anxiety-related disorder.

Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

Abstract: The present invention relates to a novel method of synthesis of copper (I) 5-nitrotetrazolate. Particularly, for the synthesis of the copper (I) 5-nitrotetrazolate, the present invention uses a suitable salt of 5-aminotetrazole, preferably the sulfate or the nitrate salt as the starting compound. The selection of the said starting chemical not only eliminates any safety issue arising during Sandmeyer reaction conditions to affect the functional group conversion but also greatly improves the ease of executing the synthetic protocol, rendering the process safe to be adopted for commercial manufacture of the copper (I) 5-nitrotetrazolate compound.

Abstract: The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.

Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Abstract: An organic electroluminescence device of an embodiment includes a first electrode, a second electrode, and an emission layer between the first electrode and the second electrode, wherein the emission layer includes an organometallic compound represented by Formula 1, and the emission layer may show high emission efficiency properties.

Abstract: Methods of using low dose naltrexone to treat chronic pain in a patient. The methods of using low dose naltrexone to treat chronic pain generally includes administering to the patient a first amount of naltrexone in an immediate-release agent and a second amount of naltrexone in a modified-release agent.

Abstract: The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase and uses of the same in the treatment of c-kit kinase associated diseases.

Abstract: The present invention relates to a process for extracting an alkaloid. Particularly, the present invention relates to a process for extracting Rauwolscine from plant parts of Rauwolfia genus. Specifically, the present invention relates to a process for extracting Rauwolscine with an enhanced purity i.e. >95%.

Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.

Abstract: The present disclosure proposes a BODIPY-based rhombic metal ring, its preparation method, and application in near-infrared region imaging, specifically a BODIPY-based rhombic metal ring M absorbed in the near-infrared first region formed based on a BODIPY-based 120° bipyridyl BODIPY ligand molecule 1 and a 60° methoxy platinum acceptor molecule 2, self-assembled by Pt—N metal coordination bonds. The BODIPY-based rhombic supramolecular metal ring has good solubility and near-infrared fluorescence emission, and it is wrapped by commercial amphiphilic polymer F127 carrier to form F127/M nanoparticles, which successfully have excellent photodynamic and photothermal therapeutic effects in vitro.

Abstract: Compounds of formula (I), wherein A, R, L, Z, Q1, Q2 and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Abstract: An organometallic compound represented by Formula 1: M(L1)n1(L2)n2??Formula 1 wherein, in Formula 1, M is a transition metal, L1 is a ligand represented by Formula 2A, L2 is a ligand represented by Formula 2B, n1 is 1 or 2, wherein, when n1 is 2, two groups L1 are identical to or different from each other, n2 is 1 or 2, wherein, when n2 is 2, two group L2 are identical to or different from each other, the sum of n1 and n2 is 2 or 3, and L1 and L2 are different from each other wherein X1, ring CY1, ring CY2, ring CY14, R1 to R3, R11 to R14, Z1 to Z3, a1, a2, a3, b1, and c1 are the same as described in the description, and * and *? in Formulae 2A and 2B each indicate a binding site to M in Formula 1.

Abstract: Disclosed are compositions and methods for modulating endothelial barrier function.